Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shandong Heda Group is a leading international manufacturer of cellulose ethers and plant-based capsules, primarily serving the pharmaceutical, food, and construction industries. The company is one of the world's largest producers of Hydroxypropyl Methylcellulose (HPMC), a critical excipient used in drug formulation and the production of vegetarian capsules. Through its subsidiary, Headcaps, the company provides a wide range of HPMC capsules that serve as a high-quality alternative to traditional gelatin capsules. Headquartered in Zibo, China, Shandong Heda is publicly traded and maintains a global presence with extensive manufacturing and R&D capabilities focused on high-purity cellulose derivatives. Their products are essential for controlled-release drug delivery and the growing market for vegan-friendly pharmaceutical dosage forms.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shandong Heda Group.